What is Xention?
Xention is a biopharmaceutical company focused on the discovery and development of innovative ion channel-modulating drugs. The company's primary therapeutic focus is on atrial fibrillation, a condition characterized by high unmet medical need. Xention leverages a proprietary approach to design potent and selective small-molecule drugs, targeting key ion channels such as Kv1.5 and Kir3.1/3.4 (IKACh), which are recognized as novel and promising targets for treating cardiac arrhythmias. The company has established strategic collaborations to advance its product pipeline.
How much funding has Xention raised?
Xention has raised a total of $44.9M across 4 funding rounds:
Series A
$5.7M
Series C
$6.5M
Series B
$20M
Series D
$12.7M
Series A (2003): $5.7M with participation from MVM Life Science Partners, BTG, SPARK Ventures, and Albany Ventures
Series C (2003): $6.5M led by MVM Life Science Partners and BTG International
Series B (2005): $20M supported by MVM, Enterprise VCT plc, Isis Equity Partners, Quester, BTG International, ABN AMRO Capital of Amsterdam, Cr�dit Agricole Private Equity, and Albany Ventures
Series D (2010): $12.7M featuring Seroba-Kernel Life Sciences Ltd
Key Investors in Xention
Seroba-Kernel Life Sciences Ltd
Seroba-Kernel Life Sciences Ltd is a European venture capital firm specializing in life sciences, with a focus on biotech and medtech innovations. They bring deep investment and industry experience to support entrepreneurs and build value.
MVM Life Science Partners
MVM Life Science Partners is an investment firm that provides capital for life science companies. Their involvement suggests a strategic interest in Xention's drug discovery and development capabilities.
BTG International
BTG International is a company involved in the healthcare sector, with a history of investing in and collaborating with innovative life science companies. Their participation indicates a belief in Xention's therapeutic approach.
What's next for Xention?
The recent major strategic investment signals a pivotal phase for Xention, likely enabling the company to accelerate its drug development programs and potentially move towards later-stage clinical trials. This infusion of capital is expected to bolster Xention's research and development efforts, expand its operational capacity, and support its strategic objectives in bringing novel treatments for atrial fibrillation to market. The company's focus on innovative targets and its established collaborations position it for continued growth and potential market leadership in its specialized therapeutic area.
See full Xention company page
